Merkel cell carcinoma is an aggressive skin carcinoma that, when advanced or metastatic, is typically treated with chemotherapy, which often leads to resistance.
Neuroblastoma, an aggressive malignancy originating from neural crest cells, accounts for 15% of cancer-related deaths in children. Treatment strategies include systemic chemotherapy, radiation or immunotherapy with anti-GD2 antibodies, all with severe side effects and long-term toxicity. Retinoic acid (RA) has been shown to promote neuroblastoma growth inhibition while suppressing MYCN oncogene expression. However, its effect is reversible, and tumor regrowth may occur.
Novel therapeutic strategies are needed to overcome drug resistance and ensure prolonged remission in multiple myeloma (MM) patients. The coactivator-associated arginine methyltransferase 1 (CARM1) is overexpressed in MM and correlated with poor prognosis and, therefore, has been proposed as a potential therapeutic target.
Multiple endogenous retroviruses (ERVs) in human DNA may be programmed to activate as cancer therapy. A recent study, led by scientists at the Dana-Farber Cancer Institute, expanded on a previously reported case of kidney cancer cure after hematopoietic stem cell transplantation attributed to the expression of an ERV driven by the hypoxia-inducible factor 2 (HIF2). The question was whether this finding might play out with different ERVs and different types of cancer through HIF.
Scientists at the University of Wisconsin Madison and Dana-Farber Cancer Institute recently presented preclinical data for the radiopharmaceutical therapy candidate [177Lu]PNT-6555.
Dana-Farber Cancer Institute Inc. has identified alkylamine-containing small-molecule B-cell lymphoma 6 protein (BCL6) degradation inducers potentially useful for the treatment of lymphoma.
Dana-Farber Cancer Institute Inc. has disclosed covalent inhibitors of serine/threonine-protein kinase A-Raf (ARAF) reported to be useful for the treatment of carcinoma and melanoma.
Research at Dana-Farber Cancer Institute Inc. has led to the identification of new interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase ligand binding moiety covalently linked to an histone deacetylase 6 (HDAC6)/8 (HDAC8)-targeting moiety through a linker.
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) ligase binding moiety covalently bonded to a histone deacetylase (HDAC) targeting moiety through a linker.
